-
Posted by
Two Blokes Apr 15 -
Filed in
Stock
-
2 views
With No Titration, Demonstrated Compelling Maximum Weight Loss of 6.3% and Mean Weight Loss of 4.3% at Day 26 at 32 mg Dose (p=0.0005) Demonstrated Strong Signal of GLP-1R Efficacy with Maximum Lowering of Fasted Glucose of -18 mg/dL and Mean Lowering of -5.3 mg/dL at Day 26 at 32 mg Dose Maximum Waist Circumference Reduction of 3.9 Inches and Mean Reduction of 1.6 Inches Demonstrates Strong Signal of Glucagon Efficacy at Day 33 at 32 mg Dose Additional Cohorts Being Added to Determine Maximum Tolerated Dose Planned Phase 1 Part 3 to Include Wegovy\u00ae Early Drop-Out Patients to Explore Potential Superiority of DA-1726 on Safety and Tolerability, Along With Weight Loss and Other Secondary Endpoints CAMBRIDGE, Mass. , April 15, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive results from the 4-week multiple ascending dose (MAD) Part 2 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity.
